| Literature DB >> 28587200 |
Eugênia Abrantes de Figueiredo1, Naiane Ferraz Bandeira Alves2, Matheus Morais de Oliveira Monteiro3, Clenia de Oliveira Cavalcanti4, Tania Maria Sarmento da Silva5, Telma Maria Guedes da Silva6, Valdir de Andrade Braga7, Eduardo de Jesus Oliveira8.
Abstract
A particularly phenolic-rich fraction extracted from red wine from the São Francisco valley (Northeastern Brazil) was chemically characterized and its hypotensive and antioxidant effects on spontaneously hypertensive rats were studied both in vitro and in vivo. The liquid-liquid pH dependent fractionation scheme afforded a fraction with high content of bioactive phenolics such as flavonols, flavonol glycosides, phenolic acids and anthocyanins, whose identities were confirmed by liquid chromatography coupled to mass spectrometry analysis. Pretreatment of spontaneously hypertensive rats with this wine fraction at doses of 50 and 100 mg/kg by gavage. for 15 days was able to decrease mean arterial pressure and heart rate as well as decrease serum lipid peroxidation. The fraction at concentrations of 0.01-1000 µg/mL induced concentration-dependent relaxation of isolated rat superior mesenteric artery rings pre-contracted with phenylephrine and this effect was not attenuated by endothelium removal. Our results demonstrate it is possible for phenolic constituents of red wine that are orally bioavailable to exert in vivo hypotensive and antioxidant effects on intact endothelial function.Entities:
Keywords: flavonoids; hypertension; phenolics; red wine
Mesh:
Substances:
Year: 2017 PMID: 28587200 PMCID: PMC5490553 DOI: 10.3390/nu9060574
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Total phenolic content of the wine fractions (expressed as gallic acid equivalents, GAE/100 mg fraction) and their antioxidant radical scavenging activity (as EC50 values). DPPH: 1,1-diphenyl-2-picrylhydrazyl radical; ABTS: 2,20-azino-bis-3-ethylbenzothiazoline-6-sulphonic acid.
| Samples | Total Phenolic Content (mg GAE/100 mg) | EC50 (µg/mL) | |
|---|---|---|---|
| DPPH | ABTS | ||
| Fr 1 SySFV | 5.57 ± 0.01 | 56.27 ± 5.50 | 90.48 ± 1.34 |
| Fr 2 SySFV | 58.45 ± 0.01 | 3.4 ± 0.03 | 4.65 ± 0.04 |
| Fr 3 SySFV | 26.29 ± 0.03 | 13.25 ± 0.07 | 11.47 ± 0.55 |
| Ascorbic acid | - | 4.38 ± 0.07 | - |
| Trolox | - | - | 3.77 ± 0.02 |
Figure 1Base peak total ion chromatogram of the wine fraction (Fr 2 SySFV) obtained by an MSE data collection technique method using ultra performance liquid chromatography coupled with time of flight mass spectrometry (UPLC-QTOF/MSE) in negative electrospray ionization mode (ESI-).
Identification of compounds present in the fraction Fr 2 SySFV by UPLC-QTOF/MS E.
| * Peak | Retention Time (min) | λmax | Compounds | Molecular Formula | [M−H]− | Fragments ( | Calc. Mass | Error (ppm) |
|---|---|---|---|---|---|---|---|---|
| 1 | 4.15 | 278 | Catechin | C15H14O6 | 289.0706 | 245.0816 | 289.0712 | 2.10 |
| 2 | 4.48 | 278 | Procyanidin dimer a | C30H26O12 | 577.1352 | 407.0798, 305.0674 | 577.1352 | 1.04 |
| 3 | 4.48 | 278 | Procyanidin dimer a | C30H26O12 | 577.1331 | 407.0758, 289.0720 | 577.1352 | 2.60 |
| 4 | 4.50 | 322 | Caffeic acid | C9H8O4 | 179.0346 | 160.8423, 135.0452 | 179.0344 | 1.11 |
| 5 | 4.71 | 278 | Epicatechin | C15H14O6 | 289.0710 | 245.0824 | 289.0712 | 0.72 |
| 6 | 4.98 | 282 | Procyanidin dimer monoglycoside | C36H36O17 | 739.1848 | 577.1340, 455.1034 | 739.1879 | >10 |
| 7 | 5.14 | 285 | Myricetin hexoside | C21H20O13 | 479.0822 | 316.0234 | 479.0825 | 0.63 |
| 8 | 5.21 | 285 | Dihydroquercetin hexoside | C21H22O12 | 465.1012 | 319.0827, 301.0351 | 465.1033 | 4.51 |
| 9 | 5.31 | 308 | C9H8O3 | 163.0399 | 119.0505 | 163.0395 | 2.45 | |
| 10 | 5.56 | 272 | Syringic acid | C9H10O5 | 197.0453 | 160.8495 | 197.0450 | 1.52 |
| 11 | 5.56 | 374 | Myricetin | C15H10O8 | 317.0301 | 259.0278 | 317.0303 | 1.26 |
| 12 | 5.70 | ND | Epigallocatechin-coumaroyl a | C24H20O9 | 451.1026 | 341.0581, 255.8171 | 451.1035 | 0.66 |
| 13 | 5.71 | 357 | Quercertin hexoside | C21H20O12 | 463.0852 | 300.0280, 271.0253 | 463.0876 | 5.20 |
| 14 | 5.73 | 357 | Myricetin methyl ether hexoside | C22H22O13 | 493.0988 | 449.1082, 333.0980 | 493.0988 | 1.22 |
| 15 | 5.75 | 286 | Dihydrokaempferol hexoside | C21H22O11 | 449.1085 | 285.0404, 229.1086 | 449.1085 | 0.22 |
| 16 | 6.29 | 283 | Epigallocatechin-coumaroyl a | C24H20O9 | 451.1018 | 341.0667, 271.0651 | 451.1035 | 2.43 |
| 17 | 6.34 | 358 | Myricetin dimethyl ether hexoside | C23H24O13 | 507.1122 | 477.1027, 341.1033 | 417.1114 | 3.35 |
| 18 | 6.44 | 282 | Dihydrokaempferol-rhamnoside | C21H22O10 | 433.1139 | 353.1249, 267.1602 | 433.1140 | 0.92 |
| 19 | 6.90 | 305 | Epigallocatechin-cinnamoyl | C24H20O8 | 435.1063 | 341.0666, 285.0812 | 435.1085 | 3.90 |
| 20 | 7.63 | 371 | Quercetin | C15H10O7 | 301.0345 | 273.0420, 197.8082 | 301.0348 | 1.33 |
| 21 | 7.71 | 374 | Myricetin methyl ether | C16H12O8 | 331.0448 | 301.0353, 197.8083 | 331.0459 | 3.02 |
| 22 | 8.21 | 324 | Dimethoxy-cinnamic acid | C11H12O4 | 207.0671 | 161,0255, 130.0462 | 207.0663 | 8.24 |
| 23 | 8.61 | 360 | Luteolin | C15H10O6 | 285.0404 | 239.9008, 197.8085 | 285.0399 | 1.40 |
| 24 | 8.86 | 360 | Quercetin methyl ether | C16H12O7 | 315.0510 | 300.0280, 197.8084 | 315.0510 | 1.58 |
| 25 | 9.41 | 309 | Methyl methoxycinnamate | C11H12O3 | 191.0715 | 174.9576, 145.0302 | 191.0714 | 3.66 |
* Peak number as marked in the chromatogram shown in Figure 1; ND—representative fragments were not detected; a positional isomers.
Figure 2Representative tracings illustrating the changes in pulse arterial pressure (PAP, mmHg), mean arterial pressure (MAP, mmHg) and heart rate (HR, bpm) in spontaneously hypertensive rats (SHR) pretreated with Fr 2 SySFV at 50 mg/kg (A) and 100 mg/kg (B) p.o. and in saline-treated controls.
Figure 3Effect of pre-treatment with Fr 2 SySFV on mean arterial pressure (MAP) of spontaneously hypertensive rats (SHR) at doses of 50 mg/kg p.o. (A) and 100 mg/kg p.o. (B) and on heart rate (HR) at 50 mg/kg p.o. (C) and 100 mg/kg p.o. (D) compared to saline-treated controls. * p < 0.05 and ** p < 0.005 when compared to SHR + saline group. Values are mean ± SEM., n = 7 for 50 mg/kg groups and n = 8 for 100 mg/kg groups
Figure 4Levels of serum malondialdehyde (MDA) in spontaneously hypertensive rats pre-treated with Fr 2 SySFV for 15 days p.o. at doses of 50 mg/kg and 100 mg/kg and saline-treated controls. * p < 0.05, when compared to SHR + saline group. Values are mean ± SEM., n = 5 for each group.
Figure 5Concentration–response curves showing the relaxant effect induced by Fr 2 SySFV (0.01–1000 μg/mL) in rat mesenteric artery rings pre-contracted with phenylephrine (10 μM) in presence () and absence () of functional endothelium. Results are expressed as mean ± SEM; n = 7 for rings with intact endothelium and n = 8 for rings with denuded endothelium.